TrueLab TrueLab Care
Evidence reviews · DOI-cited sources · research use only
Research 07 Nov 2026 · 4 min read · 4 sources

TRIUMPH-1: what the first phase 3 retatrutide trial actually measured

The phase 2 record for retatrutide was 338 people over 48 weeks. TRIUMPH-1 is 2,339 people over 80 weeks, peer-reviewed in the New England Journal of Medicine. This is the trial that moves the compound from a promising signal to a registration dossier, and the numbers deserve a closer read than the headline.

TL

TrueLab Research Team

Reviewed 07 Nov 2026 · Summarises peer-reviewed literature · Not medical advice

Key takeaways

  • TRIUMPH-1 randomised 2,339 adults with obesity or overweight and no diabetes to placebo or once-weekly retatrutide at 4, 9 or 12 mg for 80 weeks[^1].
  • Mean body-weight change at 80 weeks was −17.6%, −23.7% and −25.0% across the three doses under the treatment-regimen estimand, against −3.9% on placebo[^1].
  • The company's topline figure of −28.3% at 12 mg comes from the efficacy estimand, which handles missing data differently; both are real, and they answer different questions[^2].
  • Secondary outcomes included knee-osteoarthritis pain and obstructive sleep apnoea severity, which is why a weight trial carries a joint-pain endpoint[^1].
  • The compound remains unapproved. Lilly has stated a biologics licence application is planned for the first quarter of 2027[^3].

The earlier article on this site covered the retatrutide phase 2 programme and ended on a caveat: no phase 3 outcome data. That caveat has partly expired. TRIUMPH-1, the first of the pivotal obesity trials, was reported as topline results in May 2026 and published in full in the New England Journal of Medicine in September 202612.

This article works through what the trial was built to measure, what it found, and why the same trial produces two different headline numbers depending on who is quoting it.

The design

TRIUMPH-1 enrolled 2,339 adults with obesity, or overweight with at least one weight-related condition, and without type 2 diabetes. Participants were randomised to placebo or to once-weekly subcutaneous retatrutide at a maintenance dose of 4 mg, 9 mg or 12 mg, and followed for 80 weeks1.

Three things distinguish it from the phase 2 trial that preceded it4. It is roughly seven times larger. It runs 32 weeks longer. And it was designed to support a regulatory filing rather than to find a dose, which means the endpoints, the statistical plan and the handling of missing data were fixed in advance and are now part of the public record.

The primary result

Body-weight change at 80 weeks, TRIUMPH-1 (treatment-regimen estimand)

Mean percentage change from baseline, n=2,339

Placebo −3.9% 4 mg −17.6% 9 mg −23.7% 12 mg −25.0%

Data from Jastreboff et al., NEJM 2026 [1]. Chart by TrueLab Care.

Under the treatment-regimen estimand, mean body-weight change from baseline at 80 weeks was −17.6% at 4 mg, −23.7% at 9 mg and −25.0% at 12 mg, compared with −3.9% on placebo1.

Those are the figures in the peer-reviewed paper. They are also lower than the figures that circulated after the May topline release, which reported −19.0%, −25.9% and −28.3% for the same three doses, with −2.2% on placebo2. Both sets are correct. The difference is the estimand.

Two estimands, two answers

Same trial, two ways of counting: 12 mg at 80 weeks

Treatment-regimen vs efficacy estimand

Treatment-regimen −25.0% Efficacy estimand −28.3%

NEJM paper [1] and Lilly topline release [2]. Chart by TrueLab Care.

An estimand is a precise statement of what a trial is estimating, including how participants who stop treatment or drop out are counted. Modern obesity trials pre-specify at least two.

The treatment-regimen estimand asks: what happened to everyone who was randomised, whether or not they stayed on the drug? A participant who stopped injecting at week 30 and regained weight still counts in the group they were assigned to. This is closest to real-world use and is the more conservative number.

The efficacy estimand asks: what did the drug do in people who actually took it as directed? Data after discontinuation are handled as if treatment had continued. This number is larger, and it is the one companies tend to lead with in press releases.

Neither is wrong, but they are not interchangeable, and secondary coverage that quotes −28.3% as "the phase 3 result" without stating the estimand is quoting the more flattering of two pre-specified answers. For a reader trying to understand what the compound does to a population over 80 weeks, the treatment-regimen figure is the more honest one.

Secondary endpoints that explain the trial's shape

TRIUMPH-1 reported reductions in knee-osteoarthritis pain and in the severity of obstructive sleep apnoea alongside the weight endpoint1. This looks odd for an obesity trial until one notices that the registration programme was designed to support several indications at once: obesity itself, sleep apnoea and osteoarthritis-related knee pain are the three named in Lilly's filings3. Collecting those endpoints inside the first pivotal trial means they do not require separate programmes.

What TRIUMPH-1 does not settle

Durability after stopping. Eighty weeks of exposure says nothing about what happens at week 120 without the compound. Weight regain after discontinuation is a documented feature of the incretin class, and this trial was not designed to measure it.

Rare adverse events. A trial of 2,339 people can characterise events that occur in roughly one in a few hundred participants. It cannot characterise events that occur in one in ten thousand. That is what post-marketing surveillance is for, and it has not started.

Generalisability. Participants were selected, monitored, and dose-escalated under protocol. The treatment-regimen estimand brings the result closer to real-world conditions than the efficacy estimand does, but it is still a trial population.

Status

Retatrutide is not approved in any jurisdiction. Lilly has stated that the clinical data package is complete and that a biologics licence application to the U.S. FDA is planned for the first quarter of 20273. Review timelines after submission are typically ten to twelve months, which places any approval decision in 2028 at the earliest.

Until then, material labelled retatrutide is a research compound. The trial literature describes what the molecule does under controlled conditions; it does not describe, and cannot describe, what an unverified vial of unknown provenance does.

References

  1. 1. Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine 2026 doi:10.1056/NEJMoa2604169 ↩
  2. 2. Eli Lilly and Company Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. Press release, 21 May 2026. investor.lilly.com 2026 investor.lilly.com ↩
  3. 3. Eli Lilly and Company Form 8-K, second quarter 2026 sales and earnings. U.S. Securities and Exchange Commission 2026 www.sec.gov ↩
  4. 4. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple, Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. New England Journal of Medicine 2023 ; 389(6):514-526 doi:10.1056/NEJMoa2301972 ↩

This article summarises published research for educational purposes. It is not medical advice and does not describe permitted uses of any product. Compounds discussed are supplied strictly for in-vitro laboratory research and are not for human or animal consumption.

Continue reading

All The Science →